New York, United States
Neurobit, founded in 2021, is at the forefront of merging AI with biotechnology to revolutionize the healthcare and wellness sectors globally. Their innovative approach leverages sleep as a biomarker to predict significant health challenges like heart failure, strokes, and dementia—conditions affecting millions annually.
The company employs advanced AI models trained on extensive physiological data, positioning them as potential leaders in universal health analytics. This technology serves over 120 universities, hospitals, and research centers worldwide, indicating strong trust and adoption in the academic and clinical communities.
With its headquarters in the United States, Neurobit recently secured a $100.00K Angel Round investment on 01 April 2023. Operating at the intersection of several high-growth industries, Neurobit is poised for substantial impact and scalability, offering investors a promising opportunity amidst the evolving landscape of AI-driven healthcare.
